This is a Prospective, Non-interventional, Multicenter, Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients with Neovascular (Wet) Age-related Macular Degeneration (nAMD). All subject who completed the parent clinical study (NCT06213038 and NCT05986864) will undergo safety and efficacy assessments up to 5 years post study drug injection.
Neovascular (Wet) Age-related Macular Degeneration
This is a Prospective, Non-interventional, Multicenter, Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients with Neovascular (Wet) Age-related Macular Degeneration (nAMD). All subject who completed the parent clinical study (NCT06213038 and NCT05986864) will undergo safety and efficacy assessments up to 5 years post study drug injection.
A Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients With nAMD
-
Ophthalmic Consultants of Boston, Boston, Massachusetts, United States, 02114
Retina Consultants of Texas, Katy, Texas, United States, 77494
Wagner Macula & Retina Center, Norfolk, Virginia, United States, 23502
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
50 Years to
ALL
No
Skyline Therapeutics,
2031-03